Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice

  title={Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice},
  author={Apurva Jain and Lawrence N. Kwong and Milind M. Javle},
  journal={Current Treatment Options in Oncology},
Opinion statementBiliary tract cancers are relatively uncommon, have an aggressive disease course and a dismal clinical outcome. Until recently, there have been very few clinical advances in the management of these patients and gemcitabine-based chemotherapy has been the only widely accepted systemic therapy. The advent of next generation sequencing technologies can potentially change the treatment paradigm of this disease. Targeted therapy directed against actionable mutations and… 

Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers

The rapidly evolving role of multimodal therapy represents the subject of this review and a variety of molecularly targeted agents have shown promising survival benefits in patients with advanced disease.

Current biologics for treatment of biliary tract cancers.

  • D. ZhaoK. Lim
  • Medicine, Biology
    Journal of gastrointestinal oncology
  • 2017
The genetic landscape of BTCs is reviewed while focusing on new molecular targets and targeted therapeutics currently being investigated in biomarker-driven clinical trials.

Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments

The established role of cytotoxic chemotherapy, targeted precision treatments and immunotherapy in what is a rapidly evolving treatment paradigm for advanced biliary tract cancer is described.

The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer

Comprehensive genomic profiling (CGP) is rapidly achieving status as an integral component of precision medicine and is starting to become invaluable in guiding the management of patients with BTC, a rare disease with dismal outcome.

IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting

TheIDH1 inhibitor ivosidenib has been the first targeted agent to show a survival benefit in a randomized phase III trial of cholangiocarcinoma patients harboring IDH1 mutations, and the preclinical rationale of its targeting is discussed.

Current and Emerging Medical Therapies for Advanced Disease in Intrahepatic Cholangiocarcinoma

This chapter will review current and emerging systemic treatment options for cholangiocarcinoma and gallbladder carcinoma.

ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway

The genomic landscape of a CCA patient cohort using next-generation sequencing (NGS) is described, focusing on the ERBB/EFGR pathway and assessing response to anti-HER2 agents, suggesting that CCAs may harbor targetable alterations, especially in the ER BB/EGFR pathway.

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges

This review will discuss recent results of clinical trials testing targeted therapies in BRAF-mutant BTCs, with a particular focus on the recently published Phase II ROAR trial and ongoing active and recruiting clinical trials.



Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

GAs in the chromatin modulating genes, BAP1 and PBRM1 were associated with bone metastases and worse survival in extrahepatic CCA, and NGS can potentially identify disease subsets with distinct prognostic and therapeutic implications.

Genomic spectra of biliary tract cancer

The subgroup with the poorest prognosis had significant enrichment of hypermutated tumors and a characteristic elevation in the expression of immune checkpoint molecules, suggesting immune-modulating therapies might also be potentially promising options for these patients.

Cholangiocarcinoma: molecular pathways and therapeutic opportunities.

As the mutational landscape of CCA is being illuminated, molecular profiling of patient tumors will enable identification of specific mutations and the opportunity to offer directed, personalized treatment options.

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

Two thirds of patients in this study harbored genomic alterations that are associated with targeted therapies and that have the potential to personalize therapy selection for to individual patients.

Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations.

Pat characteristics were similar for all three tumor types, and IHCCA and GBCa were more common in females and EHCCa was more common males.

HER2/neu-directed therapy for biliary tract cancer

HER2/neu blockade is a promising treatment strategy for gallbladder cancer patients with gene amplification and deserves further exploration in a multi-center study.

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma differs significantly from intrahepatics cholangsiocARCinoma and pancreatic adenocarc inoma, and reveals diverse opportunities for the use of targeted therapies.

Mutational landscape of intrahepatic cholangiocarcinoma.

The identification of an ICC-specific somatic mutational signature that is associated with liver inflammation, fibrosis and cirrhosis is identified, and 25 significantly mutated genes including eight potential driver genes are uncovered.

Targeted Therapy in Biliary Tract Cancers

This review will discuss the various molecular pathways implicated in biliary tract cancers and potential therapeutic targets and discuss the current standard of care in the metastatic setting.

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

FGFR2 fusions and ERRFI mutations may represent novel targets in sporadic intrahepatic cholangiocarcinoma and trials should be characterized in larger cohorts of patients with these aberrations.